Une tumeur rare de la voie biliaire principale

Hachicha, L.; Châari, C.; Ellouze, S.; Gheriani, Makki; Abid, M.; Boudawara, T.

doi:10.1016/j.annpat.2010.08.023

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty-three (45%) of the 51 patients with hepatobiliary MS presented with isolated MS, either on presentation or at relapse [9,17,24,26,27,30,33,34,40,41,42,44,45,46,48,49,50,51,52,53,54,57]; 7 of them developed systemic AML within a period of 1-16 months [9,17,26,27,41,48,51] (table 1). Four of these 7 patients underwent surgery at the time of MS diagnosis, followed by chemotherapy after the development of systemic AML [9,27,41,48], with a few sustainable remissions [27,41,48]. Of 8 patients with no prior or eventual diagnosis of BM disease [24,30,40,42,50,53,54], most had upfront resections due to preoperative diagnoses of solid tumor malignancies, followed by chemotherapy; 5 remained in remission at the time of reports [24,30,40,42,50].…”

Section: Discussionmentioning

confidence: 99%

Myeloid Sarcoma of the Hepatobiliary System: A Case Series and Review of the Literature

et al. 2016

View full text Add to dashboard Cite

Myeloid sarcoma (MS) is a rare extramedullary presentation of myeloid malignancies, most commonly seen in association with acute myeloid leukemia (AML). Although MS can develop in any organ, the involvement of the hepatobiliary system is rare. With clinical manifestations of jaundice, abdominal pain and other gastrointestinal symptoms, MS presenting at this location can be a challenge to diagnose, particularly in patients with no known history of hematologic malignancy. This may cause delay in proper management. Here we report 3 cases from a single institution and a review of the literature concerning the epidemiology, clinical presentation, treatment and outcomes in patients with MS of the liver, biliary tree and pancreas.

show abstract